ALLO (Allogene Therapeutics) Days Inventory : 0.00 (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Allogene Therapeutics Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Allogene Therapeutics's Average Total Inventories for the three months ended in Sep. 2024 was $0.00 Mil. Allogene Therapeutics's Cost of Goods Sold for the three months ended in Sep. 2024 was $0.00 Mil.

The historical rank and industry rank for Allogene Therapeutics's Days Inventory or its related term are showing as below:

ALLO's Days Inventory is not ranked ^*
in the Biotechnology industry.
Industry Median: 182.54
* Ranked among companies with meaningful Days Inventory only.

Allogene Therapeutics's Days Inventory stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Allogene Therapeutics Days Inventory Historical Data

The historical data trend for Allogene Therapeutics's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allogene Therapeutics Days Inventory Chart

Allogene Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Inventory

Get a 7-Day Free Trial

Allogene Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Allogene Therapeutics's Days Inventory

For the Biotechnology subindustry, Allogene Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allogene Therapeutics's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allogene Therapeutics's Days Inventory distribution charts can be found below:

* The bar in red indicates where Allogene Therapeutics's Days Inventory falls into.

Allogene Therapeutics Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Allogene Therapeutics's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

	Days Inventory (A: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Allogene Therapeutics's Days Inventory for the quarter that ended in Sep. 2024 is calculated as:

	Days Inventory (Q: Sep. 2024 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Jun. 2024 )	+	Total Inventories (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Allogene Therapeutics (NAS:ALLO) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Allogene Therapeutics's Inventory Turnover for the three months ended in Sep. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Allogene Therapeutics's Inventory to Revenue for the three months ended in Sep. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Allogene Therapeutics Days Inventory Related Terms

Thank you for viewing the detailed overview of Allogene Therapeutics's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Allogene Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allogene Therapeutics Inc (NAS:ALLO) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

210 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.allogene.com

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Executives

Earl Martin Douglas	officer: GENERAL COUNSEL	BIOMIMETIC THERAPEUTICS, INC., 389 NICHOL MILL LANE, FRANKLIN TN 37067
Zachary Roberts	officer: EVP of R&D	C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
David D Chang	director, officer: President and CEO	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Geoffrey M. Parker	officer: CHIEF FINANCIAL OFFICER	15 RIORDAN PLACE, MENLO PARK CA 94025
Timothy L. Moore	officer: Chief Technical Officer	C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Deborah M. Messemer	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Franz B Humer	director	388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
Arie Belldegrun	director, 10 percent owner	UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738
Yinlin Jack Chen	officer: SVP, Finance	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Stephen Mayo	director	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Lillian Smith	officer: VP, Corporate Counsel	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Veer Bhavnagri	officer: General Counsel	C/O ALLOGENE THERAPEUTICS, INC., 210 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Owen N. Witte	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Rafael Amado	officer: EVP of R&D and CMO	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Alison Moore	officer: Chief Technical Officer	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080